Abstract : Postoperative complications of cataract surgery might include posterior capsule opacification (PCO, 8-34.3%). The intraocular lens (IOL), the treatment of choice, has the potential to serve as a prophylactic drug reservoir. PubMed and Google Scholar were used to perform this systematic review. We included articles with inclusion criteria were (1) using only MTX-loaded IOL, (2) published in the last 5 years, and (3) available in full text, in English. Methotrexate-poly(lactic-co-glycolic) acid (MTX-PLGA) showed a significant capability of reducing human lens epithelial cell growth (p<0,001). MTX caused a considerable increase in the time required for the posterior capsule to be completely covered with cells (P=0.046). Over the course of 14 days, it demonstrated an initial concentration peak followed by a steady release of MTX. Modification of IOL as drug delivery can be achieved by coating, soaking, or loading with haptics. Methotrexate's biological effect resulted in a long-term inhibition of cellular proliferation without harming endothelial cells. It also has a similar favorable effect on other fibrotic responses as PCO. PLGA encapsulates and stores a substantial amount of the drug, enabling the development of a slow-release device that delivers the drug continuously. Methotrexate-loaded IOL is a potential treatment in the prevention of PCO after cataract surgery.